Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis
1. MDGL reported significant two-year results for Rezdiffra in MASH cirrhosis. 2. Patients showed a 6.7 kPa reduction in liver stiffness after treatment. 3. Over 51% of patients saw a notable improvement in liver condition. 4. The company beat loss estimates and reported strong sales figures. 5. MDGL's stock rose 20.30% following the update on clinical trial results.